(Q44117573)

English

Divalproex extended-release versus the original divalproex tablet: results of a randomized, crossover study of well-controlled epileptic patients with primary generalized seizures

scientific article published in August 2002

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Divalproex extended-release versus the original divalproex tablet: results of a randomized, crossover study of well-controlled epileptic patients with primary generalized seizures (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

author name string

Manon Thibault

1

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Warren T Blume

2

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Jean-Marc Saint-Hilaire

3

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Rafik Zakhari

4

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Kenneth W Sommerville

5

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

publication date

1 August 2002

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Epilepsy Research

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

50

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

243-249

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Safety and efficacy of divalproex sodium monotherapy in partial epilepsy: a double-blind, concentration-response design clinical trial. Depakote Monotherapy for Partial Seizures Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900048-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of the bioavailability of unequal doses of divalproex sodium extended-release formulation relative to the delayed-release formulation in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900048-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Glipizide. A review of the pharmacoeconomic implications of the extended-release formulation in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900048-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Noncompliance may render migraine prophylaxis useless, but once-daily regimens are better

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900048-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Novel drug-delivery systems for hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900048-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0920-1211(02)00048-7

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44117573&oldid=2106757163"